CSL Ltd Annual Report 2021

14 Share Information CSL Limited Issued Capital Ordinary Shares: 455,125,994 as at 30 June 2021; 455,128,517 as at 11 August 2021. Details of incorporation CSL’s activities were carried on within the Commonwealth Department of Health until the Commonwealth Serum Laboratories Commission was formed as a Statutory Act 1961 (Cth) (the CSL Act) on 2 November 1961. On 1 April 1991, the Corporation was converted to a public company limited by shares under the Corporations Law of the Australian Capital Territory and it was renamed Commonwealth Serum Laboratories Limited. These changes were brought into effect by the Commonwealth Serum Laboratories (Conversion into Public Company) Act 1990 (Cth). On 7 October 1991, the name was changed to CSL Limited. The Commonwealth divested all of its shares by public float on 3 June 1994. 1 N o changes in the holdings of five per cent or more of the voting rights in CSL Limited’s shares have been notified to CSL Limited between 1 July 2021 and 11 August 2021. 2 The percentages quoted are based on the total voting rights provided in the last substantial shareholders notice. The CSL Sale Act 1993 (Cth) amends the CSL Act to impose certain restrictions on the voting rights of persons having significant foreign shareholdings, and certain restrictions on CSL itself. CSL ordinary shares (being the only class of shares on issue) have been traded on the Australian Securities Exchange (ASX) since 30 May 1994. Melbourne is the Home Exchange. In June 2014, CSL commenced a sponsored Level 1 American Depository Receipts (ADR) programwith the Bank of New York Mellon. The sponsored ADR program replaced the unsponsored ADR programs that have previously operated with CSL’s involvement. The ADRs are tradeable via licensed US brokers in the ordinary course of trading in the Over-The-Counter (OTC) market in the US. Particulars for the sponsored ADR program are: US Exchange – OTC and DR Ticker Symbol – CSLLY. Substantial shareholders The following table shows holdings of five per cent or more of voting rights in CSL Limited’s shares as notified to CSL Limited under the Australian Corporations Act 2001, Section 671B as at 30 June 2021. 1 Date of last notice Title of class Identity of person or group Date received Date of change Number owned % of total voting rights 2 Ordinary Shares Vanguard Group Inc 5 November 2018 31 October 2018 22,656,088 5.002% Ordinary Shares Blackrock Group 2 December 2019 28 November 2019 27,353,205 6.02% Voting rights – ordinary shares At a general meeting, subject to restrictions imposed on significant foreign shareholdings and some other minor exceptions, on a show of hands each shareholder present has one vote. On a poll, each shareholder present in person or by proxy, attorney or representative has one vote for each fully paid share held. In accordance with the CSL Act, CSL’s Constitution provides that the votes attaching to significant foreign shareholdings are not to be counted when they pertain to the appointment, removal or replacement of more than one-third of the directors of CSL who hold office at any particular time. A significant foreign shareholding is one where a foreign person has a relevant interest in 5% or more of CSL’s voting shares. Distribution of shareholdings as at 11 August 2021 Range Total holders Shares % of issued capital 1 – 1,000 208,233 36,224,816 7.96 1,001 – 5,000 21,486 49,074,924 10.78 5,001 – 10,000 3,323 22,880,577 5.03 10,001 – 100,000 1,364 24,745,674 5.44 100,001 and over 54 322,202,526 70.79 Total shareholders and shares on issue 234,460 455,128,517 100.00 Unmarketable parcels Minimum parcel size Holders Shares Minimum A$500.00 parcel at A$293.25 per share (being the closing market price on 11 August 2021) 2 395 395 CSL Limited Annual Report 2020/21 155